دورية أكاديمية
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.
| العنوان: | Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy. |
|---|---|
| المؤلفون: | Streicher N; MedStar Health, Washington, DC, USA. Nicholas.S.Streicher@medstar.net.; Georgetown University School of Medicine, Pasquerilla Healthcare Center (PHC), 7th Floor, 3800 Reservoir Road NW, Washington, DC, 20007, USA. Nicholas.S.Streicher@medstar.net., Amass L; Pfizer Inc, New York, NY, USA., Wang R; Pfizer Inc, New York, NY, USA., Stephens JM; OPEN Health, Bethesda, MD, USA., LeMasters T; OPEN Health, Bethesda, MD, USA., Raina R; OPEN Health, Bethesda, MD, USA., Merrill E; MedStar Health, Washington, DC, USA., Sheikh FH; MedStar Health, Washington, DC, USA.; Georgetown University School of Medicine, Pasquerilla Healthcare Center (PHC), 7th Floor, 3800 Reservoir Road NW, Washington, DC, 20007, USA. |
| المصدر: | Cardiology and therapy [Cardiol Ther] 2024 Jun; Vol. 13 (2), pp. 359-368. Date of Electronic Publication: 2024 Mar 23. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Healthcare Country of Publication: England NLM ID: 101634495 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8261 (Print) Linking ISSN: 21936544 NLM ISO Abbreviation: Cardiol Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Springer Healthcare |
| مستخلص: | Introduction: Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR-PN, while high-dose tafamidis (80/61 mg po qd) is approved worldwide to reduce cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM. The objective of this study was to assess the real-world benefit of high-dose tafamidis for delaying neurologic progression in patients with mixed-phenotype variant ATTR-CM (ATTRv-CM). Methods: This exploratory, retrospective, observational cohort study evaluated anonymized electronic medical records and included adult patients with mixed-phenotype ATTRv-CM treated with high-dose tafamidis for at least 6 months. Neurologic assessments included the Medical Research Council (MRC) Scale for Muscle Strength, Neuropathy Impairment Score (NIS) muscle weakness subscale, and Polyneuropathy Disability (PND) instrument. Modified body mass index (mBMI) was also assessed. Results: Patients (N = 10) started tafamidis treatment an average of 3.8 months after diagnosis, with an average treatment duration of 20.8 months. Seven of 10 patients demonstrated normal muscle strength on the MRC scale throughout the study, and 9 of 10 patients had no decline in muscle strength during the post-treatment period. The NIS muscle weakness subscale score was ≤ 60 for all patients in the study at all time points, suggesting normal function to mild impairment. Six of 10 patients had no change in walking capacity as measured by the PND instrument at pre- and post-assessments, while one-third of patients had a decrease in PND stage (signaling improvement) from pre- to post-assessment. mBMI remained relatively stable throughout the study. Conclusion: This is the first real-world study to demonstrate the potential value of high-dose tafamidis for delaying neurologic disease progression in patients with mixed-phenotype ATTRv-CM. The findings underscore the importance of multidisciplinary assessment for patients with ATTR amyloidosis. Trial Registration: ClinicalTrials.gov: NCT05139680. (© 2024. The Author(s).) |
| References: | Orphanet J Rare Dis. 2013 Feb 20;8:31. (PMID: 23425518) Circ Heart Fail. 2017 Jun;10(6):. (PMID: 28611125) Neurol Ther. 2018 Jun;7(1):87-101. (PMID: 29633228) J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. (PMID: 31171094) Neurol Ther. 2018 Jun;7(1):141-154. (PMID: 29611130) Circ Heart Fail. 2015 May;8(3):519-26. (PMID: 25872787) Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34. (PMID: 22645360) Orphanet J Rare Dis. 2023 Nov 10;18(1):350. (PMID: 37946256) J Neurol. 2013 Nov;260(11):2802-14. (PMID: 23974642) Drug Des Devel Ther. 2021 Mar 18;15:1225-1243. (PMID: 33776421) Cardiol Ther. 2024 Mar;13(1):117-135. (PMID: 38117424) Eur J Heart Fail. 2023 Apr;25(4):515-524. (PMID: 36644836) J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. (PMID: 27386769) Amyloid. 2017 Sep;24(3):194-204. (PMID: 28758793) N Engl J Med. 2018 Sep 13;379(11):1007-1016. (PMID: 30145929) J Neurol Sci. 2016 Mar 15;362:266-71. (PMID: 26944161) |
| فهرسة مساهمة: | Keywords: ATTR amyloidosis; ATTR cardiomyopathy; ATTR polyneuropathy; Real-world; Tafamidis |
| سلسلة جزيئية: | ClinicalTrials.gov NCT05139680 |
| تواريخ الأحداث: | Date Created: 20240324 Latest Revision: 20240517 |
| رمز التحديث: | 20240517 |
| مُعرف محوري في PubMed: | PMC11093936 |
| DOI: | 10.1007/s40119-024-00362-9 |
| PMID: | 38521883 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2193-8261 |
|---|---|
| DOI: | 10.1007/s40119-024-00362-9 |